ONCOLYTICS BIOTECH INC 8-K

What Happened
On January 14, 2026, Oncolytics Biotech, Inc. announced the appointments of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. The company filed an Form 8‑K on January 15, 2026 (Item 8.01) attaching the press release as Exhibit 99.1.

Key Details

• Appointment announcements made via press release dated January 14, 2026; 8‑K filed January 15, 2026.
• New hires: John McAdory — Executive Vice President, Strategy and Operations; Yujun Wu — Vice President, Head of Biostatistics.
• The 8‑K is an Item 8.01 Other Events filing; the press release is included as Exhibit 99.1.
• The filing does not include additional employment agreements, compensation details, or financial statements related to the appointments.

Why It Matters
Executive hires can affect company strategy execution and clinical program oversight. For investors, these appointments signal management changes intended to strengthen strategic leadership and biostatistics capabilities, but the filing provides only the announcement (no contractual or compensation details). This is an operational/management update, not an earnings or financial-results filing.